Drug General Information
Drug ID
D0B4DP
Former ID
DNC012611
Drug Name
2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline
Drug Type
Small molecular drug
Indication Discovery agent Investigative [526618]
Structure
Download
2D MOL

3D MOL

Formula
C14H14N2
Canonical SMILES
C1CN(CC2=CC=CC=C21)C3=CC=NC=C3
InChI
1S/C14H14N2/c1-2-4-13-11-16(10-7-12(13)3-1)14-5-8-15-9-6-14/h1-6,8-9H,7,10-11H2
InChIKey
CIOBWNSCGKJAQU-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Alpha-1D adrenergic receptor Target Info Inhibitor [526618]
Alpha-1B adrenergic receptor Target Info Inhibitor [526618]
Glutamate [NMDA] receptor subunit epsilon 2 Target Info Inhibitor [526618]
Alpha-1A adrenergic receptor Target Info Inhibitor [526618]
NMDA receptor subunit NR1 Target Info Inhibitor [526618]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
Adrenergic signaling in cardiomyocytes
Vascular smooth muscle contraction
Salivary secretionhsa04020:Calcium signaling pathway
Salivary secretionhsa04014:Ras signaling pathway
Rap1 signaling pathway
cAMP signaling pathway
Circadian entrainment
Long-term potentiation
Glutamatergic synapse
Dopaminergic synapse
Alzheimer's disease
Amyotrophic lateral sclerosis (ALS)
Huntington's disease
Cocaine addiction
Amphetamine addiction
Nicotine addiction
Alcoholism
Systemic lupus erythematosushsa04020:Calcium signaling pathway
AMPK signaling pathway
NetPath Pathway IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway
PANTHER Pathway Alpha adrenergic receptor signaling pathwayP00029:Huntington disease
Ionotropic glutamate receptor pathway
Metabotropic glutamate receptor group III pathway
Metabotropic glutamate receptor group I pathway
Muscarinic acetylcholine receptor 1 and 3 signaling pathwayP00002:Alpha adrenergic receptor signaling pathwayP00029:Huntington disease
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
Pathway Interaction Database LPA receptor mediated eventserbb4_pathway:ErbB4 signaling events
Reelin signaling pathway
Reactome Adrenoceptors
G alpha (q) signalling events
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
G alpha (12/13) signalling eventsR-HSA-3928662:EPHB-mediated forward signaling
Unblocking of NMDA receptor, glutamate binding and activation
CREB phosphorylation through the activation of CaMKII
Ras activation uopn Ca2+ infux through NMDA receptor
RAF/MAP kinase cascadeR-HSA-390696:Adrenoceptors
RAF/MAP kinase cascade
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
GPCRs, OtherWP58:Monoamine GPCRs
Vitamin D Receptor Pathway
AMPK SignalingWP666:Hypothetical Network for Drug Addiction
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
BDNF signaling pathwayWP58:Monoamine GPCRs
Endothelin Pathways
AMPK SignalingWP706:SIDS Susceptibility Pathways
Hypothetical Network for Drug Addiction
Spinal Cord Injury
BDNF signaling pathway
Alzheimers Disease
References
Ref 526618Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists.
Ref 526618Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62.4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.